Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 11;13(6):tfae182.
doi: 10.1093/toxres/tfae182. eCollection 2024 Dec.

Efficacy and safety assessment of probiotic Bacillus coagulans (Heyndrickxia coagulans) BCP92 for treatment of diarrhea

Sohel S Shaikh  1 , Snehal Patel  2 , Anis Malik  1 , Aakash Kumar S  2
Affiliations

Efficacy and safety assessment of probiotic Bacillus coagulans (Heyndrickxia coagulans) BCP92 for treatment of diarrhea

Sohel S Shaikh et al. Toxicol Res (Camb). .

Erratum in

Abstract

Objective: Probiotics offer a potentially new therapeutic approach for the treatment of diarrhea. This study aimed to determine the anti-diarrheal activity of Bacillus coagulans BCP92 (MTCC 25460) and its safety assessment (acute and sub-acute toxicity studies) in animal models and cell lines.

Methods: The antidiarrheal activity was studied in mice using a castor oil-induced diarrhea model. In the acute toxicity study, the rats were orally fed 2000 mg/kg (4 × 1011 CFU/g) of B. coagulans BCP92 (MTCC 25460) as a single dose, and for sub-acute toxicity study rats received 250, 500, and 1,000 mg/kg/day for 28 days. At the end of the treatment, body weight, organ weight, food intake, biochemical parameters, hematological parameters, and histopathology were studied. B. coagulans BCP92 is effective against diarrhea by reducing the onset of diarrhea (latency), frequency of defecation, total fecal weight, and percentage of defecation. In-vitro MTT assay was performed on Vero cell lines.

Results: In-vitro MTT assay showed a cytoprotective effect. In acute toxicity study, 2000 mg/kg dose did not cause any alteration in clinical signs, morbidity, or mortality. The findings of the subacute toxicity study showed no alterations in physical appearance and behavioral patterns. Moreover, no significant variations were found in organ weights and hematological and biochemical parameters of the treated groups in the control group. Furthermore, no visible histological changes were observed in the heart, lung, liver, and kidney of the high-dose treatment groups.

Conclusion: Thus, the results of the present study conclude that B. coagulans BCP92 is safe for human use in the treatment of diarrhea.

Keywords: Acute toxicity; Antidiarrheal; Bacillus coagulans; Cytotoxicity; Sub-acute toxicity.

PubMed Disclaimer

Conflict of interest statement

The authors confirm the content of manuscript and that they have no conflict of interest.

References

    1. FAO/WHO . Guidelines for the evaluation of probiotics in food. Paris: FAO; 2002. pp. 1–11.
    1. Honda H, Hoyles L, Gibson G, Farmer S, Keller D, McCartney AL. Impact of GanedenBC30 (Bacillus coagulans GBI-30, 6086) on population dynamics of the human gut microbiota in a continuous culture fermentation system. Int J Probiot Prebiot. 2011:6(1):65–72.
    1. Salminen S, Ouwehand AC, Isolauri E. Clinical applications of probiotic bacteria. Int Dairy J. 1998:8(5–6):563–572.
    1. Cao J, Yu Z, Liu W, Zhao J, Zhang H, Zhai Q, Chen W. Probiotic characteristics of Bacillus coagulans and associated implications for human health and diseases. J Funct Foods. 2020:64:103643.
    1. Lee NK, Kim WS, Paik HD. Bacillus strains as human probiotics: characterization, safety, microbiome, and probiotic carrier. Food Sci Biotechnol. 2019:28(5):1297–1305. - PMC - PubMed

LinkOut - more resources